Prevent immunogenicity surprises
in the clinic.
Who We Are
Fearless Science.
EpiVax leads the industry in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. Utilizing proprietary methods for T cell epitope identification and characterization, we employ a wide range of validated in silico and in vitro techniques. This comprehensive approach provides accurate and thorough insights into candidate immunogenicity, ensuring the effectiveness and safety of our clients’ products.
12M+
sequences analyzed
17
of the 20 top pharmaceutical companies served
500+
industry, agency, & academic collaborators
26
years experience
220+
peer-reviewed publications
News
Thinking Out Loud: October 2024
October is Rocking! Off to Amsterdam and...
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
PROVIDENCE, R.I., Oct. 24,...
Thinking Out Loud: October 2024
October is Rocking! Off to Amsterdam and...
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
PROVIDENCE, R.I., Oct. 24,...
The Amsterdam Immunogenicity and Tolerance Seminar: 2024
The 10th annual Amsterdam Immunogenicity and...